Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–75.

Article  PubMed  Google Scholar 

Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016;374(3):254–62.

Article  CAS  PubMed  Google Scholar 

Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract. 2020;26(Suppl 1):1–46.

Article  PubMed  Google Scholar 

Kanis JA, Harvey NC, McCloskey E, Bruyere O, Veronese N, Lorentzon M, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12.

Article  CAS  PubMed  Google Scholar 

El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;142(25):e506–32.

Article  PubMed  Google Scholar 

Rosano GM, Vitale C, Marazzi G, Volterrani M. Menopause and cardiovascular disease: the evidence. Climacteric. 2007;10(Suppl 1):19–24.

Article  CAS  PubMed  Google Scholar 

Lim SY, Bolster MB. Profile of romosozumab and its potential in the management of osteoporosis. Drug Des Dev Ther. 2017;11:1221–31.

Article  CAS  Google Scholar 

Rauner M, Taipaleenmaki H, Tsourdi E, Winter EM. Osteoporosis treatment with anti-sclerostin antibodies-mechanisms of action and clinical application. J Clin Med. 2021;10(4):787.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, et al. Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res. 2019;34(9):1597–608.

Article  CAS  PubMed  Google Scholar 

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43.

Article  CAS  PubMed  Google Scholar 

Turk JR, Deaton AM, Yin J, Stolina M, Felx M, Boyd G, et al. Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Regul Toxicol Pharmacol. 2020;115:104697.

Article  CAS  PubMed  Google Scholar 

Zheng J, Wheeler E, Pietzner M, Andlauer TFM, Yau MS, Hartley AE, et al. Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomization. Arthritis Rheumatol. 2023;75(10):1781–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–27.

Article  CAS  PubMed  Google Scholar 

Wu ST, Chen JF, Tsai CJ. The impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular disease. J Formos Med Assoc. 2021;120(11):1957–66.

Article  CAS  PubMed  Google Scholar 

Casula M, Olmastroni E, Galimberti F, Tragni E, Corrao G, Scotti L, et al. Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: a population-based study. Atherosclerosis. 2020;301:1–7.

Article  CAS  PubMed  Google Scholar 

Rodriguez AJ, Ernst MT, Nybo M, Prieto-Alhambra D, Ebeling PR, Hermann AP, et al. Oral bisphosphonate use reduces cardiovascular events in a cohort of Danish patients referred for bone mineral density. J Clin Endocrinol Metab. 2020;105(10):3215–25.

Article  Google Scholar 

Kobayakawa T, Suzuki T, Nakano M, Saito M, Miyazaki A, Takahashi J, et al. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study. Bone Rep. 2021;14: 101068.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y. Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep. 2021;11(1):11801.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906.

Article  PubMed  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.

Article  PubMed  Google Scholar 

Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4): e1003082.

Article  PubMed  PubMed Central  Google Scholar 

Baek KH, Chung YS, Koh JM, Kim IJ, Kim KM, Min YK, et al. Romosozumab in postmenopausal korean women with osteoporosis: a randomized, double-blind, placebo-controlled efficacy and safety study. Endocrinol Metab (Seoul). 2021;36(1):60–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab. 2000;85(11):4118–24.

Article  CAS  PubMed  Google Scholar 

Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87(10):4528–35.

Article  CAS  PubMed  Google Scholar 

Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153–61.

Article  CAS  PubMed  Google Scholar 

Cryer B, Binkley N, Simonelli C, Lewiecki EM, Lanza F, Chen E, et al. A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am J Geriatr Pharmacother. 2005;3(3):127–36.

Article  CAS  PubMed  Google Scholar 

Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone. 1996;18(2):141–50.

Article  CAS  PubMed  Google Scholar 

Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled european study of forsteo (EUROFORS). J Bone Miner Res. 2009;24(4):726–36.

Article  CAS  PubMed  Google Scholar 

Felsenberg D, Alenfeld F, Beck O, Hammermeister C, Gowan W, Grp FS. Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. Maturitas. 1998;31(1):35–44.

Article  CAS  PubMed  Google Scholar 

Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab. 2005;90(3):1583–7.